^
Association details:
Biomarker:ROS1 rearrangement
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study

Published date:
01/04/2022
Excerpt:
The ORR and PFS were 16.7% (n = 12) and 28.6% (n = 7), 7.8 months and 9.0 months for HER2 and EGFR Exon20 insertion patients, respectively. Three ROS1 patients were enrolled with a PFS of 16.0, 34.2, and 45.0 months individually, and one ALK patient with PFS of 4.4 months was identified....ICI-based combination therapy could be considered for patients with ROS1 rearrangement, HER2 mutation and EGFR Exon20 insertion NSCLC....All three patients with ROS1 rearrangements and ECOG 1 who received ICIs combined with chemotherapy as first-line treatment had response of PR.
Secondary therapy:
Chemotherapy
DOI:
10.20517/cdr.2021.85
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

Published date:
05/18/2021
Excerpt:
In this multi-institutional retrospective study, tumor programmed death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB) were evaluated in patients with ROS1-rearranged NSCLC. Time-to-treatment discontinuation (TTD) and objective response rate (ORR) (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) were calculated for patients treated with ICI or chemo-ICI in the metastatic setting....Among patients treated with chemo-ICI, median TTD was 10 months (95% CI: 4.7-14.1 mo; n = 11) and ORR 83% (5 of 6 RECIST-assessable; 95% CI: 36%-100%).
DOI:
10.1016/j.jtocrr.2021.100187